



...



IDEA-FAST

Year in Review

December 2025



Message from the Project Leaders

Dear all,

As 2025 draws to a close, we would like to say a big thank you for your contributions and dedication to the IDEA-FAST consortium. We would also like to take this opportunity to highlight some of our key achievements as well as challenges in 2025.

Over the past 12 months, we focused on completing recruitment to the IDEA-FAST Clinical Observational Study (COS), data quality assurance and analysis, and developing our sustainability and exploitation strategy.

We are pleased to say that a total of 1891 participants have been recruited, meeting 95% of our initial ambitious target. We have reached at least 86% of the recruitment targets for all cohorts. This is a huge achievement that could not have been realised without the commitment and hard work of all the recruiting sites. This sample size makes the IDEA-FAST study one of the largest wearable device research studies with concomitant comprehensive clinical and patient-reported outcome (PRO) data currently available worldwide.

Our data analytics teams continued to make substantial progress in data quality assurance, generating new candidate features through smarter dataset building and refining the data analytics plan accordingly. Our sustainability and exploitation team continued to increase and diversify our dissemination efforts to promote the IDEA-FAST project to the public, which helps build the foundation for sustainability and exploitation of the IDEA-FAST bioresource and assets.

Message from the Project Leaders

Our patients are at the heart of our project. Our PIE group continued to meet regularly, and members were involved in the Biomarker Selection Committee, as well as invited to participate in Steering Committee meetings.

We have also met with many challenges in 2025; the hardest was the unexpected massive data loss in March 2025. This led to the loss of almost all data from the digital devices on the IDEA-FAST Data Management Platform. But once again, our consortium partners came together to deal with this crisis effectively, and we were able to recover/re-upload the majority of the data. We are immensely grateful to all the partners involved for working tirelessly on this over 3-4 months.

Looking ahead, we anticipate our “last subject, last visit” will take place before 31st Jan 2026. Our data analytics teams will be forging ahead to complete the planned analyses. We will finalise an operable sustainability and exploitation roadmap in order to maximise the impact of IDEA-FAST both now and in the future.

These accomplishments could not be achieved without the hard work, collaboration, and effective working across different work packages of all consortium partners. A heartfelt thank you goes to you all!

Finally, we wish you a happy Christmas/festive season and a successful 2026.

Yours sincerely,

Fai, Walter, Nikolay, Geert, Dave, and Mike

Be part of IDEA-FAST

IDEA-FAST Survey for Patients

In 2025, IDEA-FAST launched the Patient Survey, aiming to hear directly from those who live with chronic conditions. Patient input will help guide the integration of digital biomarkers into healthcare and research to improve diagnosis, monitoring, and quality of life.

[Read more and fill in the Patient survey](#)

IDEA-FAST Survey for HCPs

Are you a healthcare professional who manages conditions such as Rheumatoid Arthritis, Lupus, Parkinson's Disease, or IBD?

Help us understand how digital tools and biomarkers could complement established clinical assessments and enhance decision-making in clinical care. Get involved today and play a role in shaping tomorrow's digital care solutions!

[Read more and fill in the HCP survey](#)



IDEA-FAST in 2025

Events

ISPGR 2025 World Congress - Maastricht, The Netherlands

[Read More](#)

EULAR Annual Congress 2025 - Barcelona, Spain

[Read More](#)

IDEA-FAST General Assembly 2025 - Lisbon, Portugal

[Read More](#)

7th Digital Rheumatology Day - Berlin

[Read More](#)

People of IDEA-FAST

Real-World Stories - Interview with Eden Burne

[Read More](#)

Real-World Stories - Interview with Nancy Brown

[Read More](#)

Real-World Stories - Interview with Jordi Crus Gomez

[Read More](#)

Real-World Stories - Interview with Ulli Funken

[Read More](#)

IDEA-FAST in 2025

Milestones

IDEAFAST COS (Clinical Observational Study) recruitment is complete, reaching 1891 participants across 20 sites in 10 European countries.

[Read More](#)

Conferences and Workshops

HI Real-World Evidence (RWE) Workshop - Brussels, Belgium

[Read More](#)

EMBL-EBI Industry Programme Workshop - Cambridge University

[Read More](#)

The IDEA-FAST Newsletter

The latest edition of IDEA-FAST Newsletter was released in July 2025. It offers detailed updates and news from IDEA-FAST, beyond what's covered in this brief overview.

For the [full newsletter](#), visit our website and read more about IDEAFAST news, activities and publications.

STAY UPDATED!

Follow us on:



IDEA-FAST



[idea-fast.eu](#)



innovative
medicines
initiative



The project has received funding from
the IMI2 Joint Undertaking under grant
agreement No 853981